[
  {
    "overallHR": {
      "lowerCI": 0,
      "upperCI": 0,
      "title": "Overall",
      "hazardRatio": 0
    },
    "id": 27,
    "title": "",
    "combinations": [
      3
    ],
    "description": "",
    "infoPSA": "â‰¥50% decline in PSA level from baseline",
    "drugCombinations": [
      {
        "condition": 0,
        "subTitle": "",
        "dataPSA": [
          {
            "title": "Lu-PSMA-617",
            "psaResponseRate": "66",
            "timeToPSAProgression": "Not Reported",
            "objectiveDiseaseProgression": ""
          },
          {
            "title": "Cabazitaxel",
            "psaResponseRate": "37",
            "timeToPSAProgression": "Not Reported",
            "objectiveDiseaseProgression": ""
          }
        ],
        "figures": [
          {
            "value": 0,
            "caption": "RADIOGRAPHIC PROGRESSION FREE SURVIVAL (rPFS)",
            "image": "TheraP_rpfs",
            "description": ""
          },
          {
            "value": 0,
            "caption": "OVERALL SURVIVAL (OS)",
            "image": "TheraP_os",
            "description": ""
          }
        ]
      }
    ],
    "hazardRatioTitle": "",
    "hazardRatios": [],
    "note": "",
    "references": "[1] Bolhuis, K. et al. (2022) External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of olorectal Liver Metastases in a Nationwide Cohort, Cancers, 14(10), 2356, available: https://doi.org/10.3390/cancers14102356\n\n[2] Margonis, G.A., et l. (2018) Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases, British Journal of Surgery, 105(9), 1210 220, available: https://doi.org/10.1002/bjs.10838\n\n[3] Fong, Y. et al. (1999). Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 230(3), 309. https://doi.org/10.1097/00000658-199909000-00004"
  }
]